A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Nsclc
  • Age: Between 18 Year(s) - 75 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically or cytology-confirmed, locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC that cannot be completely resected by surgery and cannot receive radicalconcurrent/sequential chemoradiation
    2. Prior treatment with EGFR TKI and treatment failure
    3. EGFR activation mutations that are confirmed by tumor histology or cytology or blood test before enrollment

You may not be eligible for this study if the following are true:

    1. Histologic or cytopathologic evidence of the presence of a small cell carcinoma component, or a predominantly squamous cell carcinoma
    2. Patients who have received immunotherapy in the past, including immune checkpoint inhibitors (such as anti-PD-1/L1 antibodies, anti-CTLA-4 antibodies, anti-LAG-3 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), immune cell therapy, or any other treatment that targets the mechanism of tumor immune action
    3. Received systemic antitumor therapy for the advanced stage (IIIB to IV) of NSCLC (including cytotoxic chemotherapy, systemic chemotherapy, and antiangiogenic therapy with radiotherapy) other than EGFR inhibitor drugs



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.